ArticlePloS one2013
Identification of biomarkers of response to IFNg during endotoxin tolerance: application to septic shock.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.Rheumatology (Oxford, England) · 2021Pooled it
- Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.Cell reports. Medicine · 2022Trial
- Article
- Conditional Tnfaip6-Knockout in Inner Ear Hair Cells Does not Alter Auditory Function.Neuroscience bulletin · 2025Article
- Article
- The progress of organ protection mechanisms in sepsis.Frontiers in immunology · 2025Review
- Evaluating the Causal Effects of Circulating Proteome on the Risk of Sepsis and Related Outcomes.ACS omega · 2024Article
- Novel RNA biomarkers improve discrimination of children with tuberculosis disease from those with non-TB pneumonia afterFrontiers in immunology · 2024Article
- Identification and experimental validation of diagnostic and prognostic genes CX3CR1, PID1 and PTGDS in sepsis and ARDS using bulk and single-cell transcriptomic analysis and machine learning.Frontiers in immunology · 2024Article
- Altered Ex Vivo NLRP3 Inflammasome Activation Is Associated with 28-Day Mortality in Septic Patients.Viruses · 2023Article
- Mapping the epigenomic landscape of human monocytes following innate immune activation reveals context-specific mechanisms driving endotoxin tolerance.BMC genomics · 2023Article
- Advances in the Study of Immunosuppressive Mechanisms in Sepsis.Journal of inflammation research · 2023Review
- Identification and validation of a novel mitochondrion-related gene signature for diagnosis and immune infiltration in sepsis.Frontiers in immunology · 2023Article
- Peripheral blood mononuclear cell phenotype and function are maintained after overnight shipping of whole blood.Scientific reports · 2022Article
- Prominent Indomethacin-Induced Enteropathy in FcgriibInternational journal of molecular sciences · 2021Article
- The role and function of IκKα/β in monocyte impairment.Scientific reports · 2020Article
- Loss of mitochondrial ClpP, Lonp1, and Tfam triggers transcriptional induction of Rnf213, a susceptibility factor for moyamoya disease.Neurogenetics · 2020Article
- Sirtuins: potential therapeutic targets for regulating acute inflammatory response?Expert opinion on therapeutic targets · 2020Review
- Two Gene Set Variation Index as Biomarker of Bacterial and Fungal Sepsis.BioMed research international · 2020Article
- Identification of Potential Transcriptional Biomarkers Differently Expressed in BothBioMed research international · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid development in septic patients of features of marked immunosuppression associated with increased risk of nosocomial infections and mortality represents the rational for the initiation of immune targeted treatments in sepsis. However, as there is no clinical sign of immune dysfunctions, the current challenge is to develop biomarkers that will help clinicians identify the patients that would benefit from immunotherapy and monitor its efficacy. Using an in vitro model of endotoxin tolerance (ET), a pivotal feature of sepsis-induced immunosuppression in monocytes, we identified using gene expression profiling by microarray a panel of transcripts associated with the development of ET which expression was restored after immunostimulation with interferon-gamma (IFN-γ). These results were confirmed by qRT-PCR. Importantly, this short-list of markers was further evaluated in patients. Of these transcripts, six (TNFAIP6, FCN1, CXCL10, GBP1, CXCL5 and PID1) were differentially expressed in septic patients' blood compared to healthy blood upon ex vivo LPS stimulation and were restored by IFN-γ. In this study, by combining a microarray approach in an in vitro model and a validation in clinical samples, we identified a panel of six new transcripts that could be used for the identification of septic patients eligible for IFNg therapy. Along with the previously identified markers TNFa, IL10 and HLA-DRA, the potential value of these markers should now be evaluated in a larger cohort of patients. Upon favorable results, they could serve as stratification tools prior to immunostimulatory treatment and to monitor drug efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.